INS and cancer: Since decades, the association ofaberrant insulin signaling in diabetics and increased cancer risk has beenstated, and recently validated in patient studies with respect to colon,pancreas, breast, endometrium, prostate, liver, and bladder (see, e.g., [4–7]).